(object) array( 'id' => '10479591', 'url' => 'FR/actinic_keratoses_₂', 'image' => '', 'title' => 'Kératose actinique', 'tags' => array ( 0 => 'Kératose actinique', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Kératose actinique', 'source_id' => 5092398, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083418', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Lésions précancéreuses se traduisant par une zone rouge, épaisse et rugueuse ; elles apparaissent habituellement sur une peau endommagée par le soleil.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507928310838984706, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'Precancerous growths that can appear red, thick, and rough; usually found on sun-damaged skin.', 'Part of Speech' => 'noun', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'MaryK', 'Creation Date' => '2013/3/15', 'Term' => 'actinic keratoses', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'actinic_keratoses_₂', )

(object) array( 'id' => '6230217', 'url' => 'FR/investigational_new_drug_₁', 'image' => '', 'title' => 'Nouveau médicament expérimental', 'tags' => array ( 0 => 'Nouveau médicament expérimental', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Nouveau médicament expérimental', 'source_id' => 4011789, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104715', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un médicament ou produit biologique qui est utilisé dans un essai clinique, mais pas approuvé par la FDA (soit le médicament n\'est pas disponible pour la prescription par un médecin, soit il est disponible, mais pas approuvé par la FDA pour l\'utilisation en cours d\'étude).', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081755480066, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A drug, or biological product that is used in a clinical trial but has not been approved by the FDA (the drug is either not available for a doctor to prescribe or, is available, but not approved by the FDA for the use being studied).', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'investigational new drug', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'investigational_new_drug_₁', )

(object) array( 'id' => '6230216', 'url' => 'FR/primary_purpose', 'image' => '', 'title' => 'Objectif principal', 'tags' => array ( 0 => 'Objectif principal', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Objectif principal', 'source_id' => 4011788, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104714', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'L\'une des raisons principales de l\'essai clinique. Les types d\'objectifs principaux incluent le traitement, la prévention, le diagnostic, les soins de soutien, le dépistage, la recherche sur les services de santé, et la science de base.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081755480065, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The one main reason for the clinical trial. Types of primary purposes include treatment, prevention, diagnostic, supportive care, screening, health services research, and basic science.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'primary purpose', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'primary_purpose', )

(object) array( 'id' => '3898055', 'url' => 'FR/fixed_interval_₁', 'image' => '', 'title' => 'Intervalle fixe', 'tags' => array ( 0 => 'Intervalle fixe', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle fixe', 'source_id' => 3744254, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105907', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un programme dans lequel une personne est renforcée par la première réponse après qu\'une période de temps fixe soit passée depuis le renforcement précédent. Ce programme induit généralement une pause après un renforçateur puis une augmentation progressive du rythme d\'émission des réponses jusqu\'à un niveau élevé au moment où le prochain renforçateur est reçu.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851744059392, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'A schedule in which a person is reinforced for the first response after a fixed period of time has passed since the previous reinforcement. This schedule usually causes people to pause after a reinforcer and then to gradually increase their response rate until they are working at a high rate at the moment they receive the next reinforcer.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'fixed interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'fixed_interval_₁', )

(object) array( 'id' => '3898054', 'url' => 'FR/fixed-interval_₁', 'image' => '', 'title' => 'Intervalle fixe', 'tags' => array ( 0 => 'Intervalle fixe', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle fixe', 'source_id' => 3744252, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105905', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Programme de renforcement. Un renforçateur dépend de la première réponse après un intervalle de temps fixe depuis la dernière opportunité pour un renforcement.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851728330753, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'schedule of reinforcement. A reinforcer is contingent on the first response after a fixed interval of time since the last opportunity for reinforcement.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'fixed-interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'fixed-interval_₁', )

(object) array( 'id' => '3898053', 'url' => 'FR/variable_interval_₁', 'image' => '', 'title' => 'Intervalle variable', 'tags' => array ( 0 => 'Intervalle variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle variable', 'source_id' => 3744244, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105901', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => '1) Un programme dans lequel une personne est renforcée par la première réponse après qu\'une période de temps variable soit passée depuis le renforcement précédent. Ce programme produit généralement un rythme de réponse uniforme. 2) Un programme de renforcement dans lequel une réponse est renforcée après qu\'une période de temps variable soit passée. Par exemple, dans un programme IV 30 secondes, l\'intervalle de temps varie entre chaque renforcement, mais l\'intervalle moyen de temps est de 30 secondes.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851728330752, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => '1) A schedule in which a person is reinforced for the first response after a varying period of time has passed since the previous reinforcement. This schedule usually causes a person to respond at a uniform rate. 2) A schedule of reinforcement in which one response is reinforced after a variable amount of time has passed. For example, on a VI 30-second schedule, the time to each reinforcement changes but the average time is 30 seconds.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'See Also' => 'interval schedules of reinforcement_₀', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable_interval_₁', )

(object) array( 'id' => '10479588', 'url' => 'FR/Dermokil', 'image' => 'dermokillogo-1359898176.jpg;', 'title' => 'Dermokil', 'tags' => array ( 0 => 'Dermokil', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Dermokil', 'source_id' => 4925105, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083408', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Ezel Kozmetik a été fondée suite à une décision prise par l’homme d’affaire Ünal Karaca après avoir vu que l’on pouvait concevoir des produits cosmétiques à partir de sel de la mer Morte. Sur ce, il décida de produire des produits à base d\'argile qui sont utilisés depuis des siècles en Anatolie et plus récemment partout dans le monde et de promouvoir ses avantages en tant que produits cosmétiques. Les produits Dermokil (Produits Dermoclay) ont vu le jour à l’issue de 2 ans d’étude dans les laboratoires R&D et après les résultats positifs obtenus lors des essais effectués sur 2000 personnes. Les certificats d’enregistrement de marque et les rapports d’approbation établis par l’université Cumhuriyet, les matières premières et les produits ayant des rapports d’analyse microbiologique sont contrôlés par des dispositifs technologiques conformément aux normes nationales et internationales. Les analyses physiques, chimiques et microbiologiques des produits se réalisent d’une manière rapide et sûre à chaque étape de la production. L\'usine d\'Ezel Kozmetik composée d\'installations de production modernes a été établie à Sivas en 2006 et d\'une équipe de R&D composée d’ingénieurs chimistes experts en la matière, vise à devenir une marque leader dans le secteur de la cosmétique à travers ses machines de technologie avancée et son service logistique.', 'usage_comment' => '', 'glossary' => '', 'width' => 300, 'height' => 300, '_version_' => 1507928310837936128, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Dermokil', 'Definition' => 'Ezel Kozmetik was founded when Unal Karaca, the businessman, saw that the cosmetic products were made up of the salt of the Dead Sea and decided to produce the clay products which have been used in Anatolia for centuries and throughout the world during the recent years and to promote its benefits as a cosmetics. The Dermokil products (Dermoclay Products) appeared after testing on 2000 individuals and obtaining positive results and a two-year R&D study. Its brand registration certificates and the reports approved by Cumhuriyet University, the raw materials and products having microbiological analysis report are inspected by technological devices in national and international standards. In every stage of the production, the physical, chemical and microbiological analyses of the products are rapidly and reliably conducted. The factory of Ezel Kozmetik composed of the modern manufacturing plant established in Sivas in 2006 and an R&D team consisting of chemical engineers who are expert in their field aims to go ahead on the road to become a pioneer brand in the cosmetics sector through the high-tech machines and logistics services it provides.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Sample Image' => 'dermokillogo-1359898176.jpg;', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'dermokil', 'Creation Date' => '2013/2/5', 'Company' => '', 'Synonym' => '', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Dermokil', )

(object) array( 'id' => '3951142', 'url' => 'FR/Yawning-No-More', 'image' => 'yawning.jpg; bush yawning.jpg;', 'title' => 'Yawning-No-More', 'tags' => array ( 0 => 'Yawning-No-More', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Yawning-No-More', 'source_id' => 639288, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721084108', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un nouveau médicament de relaxation musculaire qui stoppe les bâillements pendant un certain nombre d\'heures. Le bâillement est une réaction allergique du corps à cause de la fatigue, du manque de stimulation, ou de l\'ennui. Yawning-No-More détend les muscles qui induisent le bâillement ainsi la personne peut éviter de bâiller jusqu\'à cinq heures. Le bâillement peut être gênant lors de rassemblements sociaux ou des réunions d\'affaires car il peut montrer un manque d\'intérêt ou d\'énergie. Ce nouveau médicament promet de changer sensiblement la façon dont la société voit le bâillement.', 'usage_comment' => '', 'glossary' => '', 'width' => 503, 'height' => 340, '_version_' => 1507294573051772928, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Yawning-No-More', 'Definition' => 'A new muscle relaxation drug that stops yawning for a number of hours. Yawing is an allergic reaction of the body due to tiredness, lack of stimulation, or boredom. Yawning-No-More relaxes the muscles that induce yawning so the person can be spared of yawning for up to five hours. Yawning can be embarrassing during social gatherings or business meetings as it may show a lack of interests or energy. This new drug promises to substantially change the way society views yawning.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Sample Image' => 'yawning.jpg; bush yawning.jpg;', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Creation User' => 'BruceLH', 'Creation Date' => '2011/1/23', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Yawning-No-More', )

(object) array( 'id' => '6229091', 'url' => 'FR/study_design', 'image' => '', 'title' => 'Plan d\'étude', 'tags' => array ( 0 => 'Plan d\'étude', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Plan d\'étude', 'source_id' => 4011443, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104709', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les méthodes d\'investigation utilisées dans l\'étude clinique. Pour les études interventionnelles, celles-ci incluent un objectif principal, un modèle d\'intervention, en insu ou en aveugle, et une affectation.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431489, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The investigative methods used in the clinical study. For interventional studies, these include primary purpose, intervention model , masking or blinding, and allocation.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'study design', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'study_design', )

(object) array( 'id' => '3897820', 'url' => 'FR/variable-interval_₁', 'image' => '', 'title' => 'Intervalle variable', 'tags' => array ( 0 => 'Intervalle variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle variable', 'source_id' => 3744241, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105901', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un renforçateur dépend de la première réponse après un intervalle de temps variable depuis la dernière opportunité pour un renforcement.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851727282176, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'A reinforcer is contingent on the first response after a variable interval of time since the last opportunity for reinforcement.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable-interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable-interval_₁', )